Direkt zum Inhalt
Merck

E0504

Sigma-Aldrich

Ecarin from Echis carinatus venom

prothrombin activator

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

CAS-Nummer:
MDL-Nummer:
UNSPSC-Code:
12352202
NACRES:
NA.61

Biologische Quelle

Echis carinatus venom

Qualitätsniveau

Verpackung

vial of 45-55 units

Lagertemp.

−20°C

Anwendung

Ecarin from Echis carinatus venom is the primary reagent in the ecarin clotting time (ECT) test, which is used to monitor anticoagulation and thrombin inhibition. It has been used in studies to test the effectiveness of medications for the treatment of venous and arterial thromboembolism.
Ecarin activity is the principal behind the Ecarin Clotting Time (ECT) assay, which is used to assess antithrombotic effect and thrombin inhibition.

Biochem./physiol. Wirkung

Prothrombin activator

Einheitendefinition

One unit will activate prothrombin to produce one unit of amidolytic activity at pH 8.4 at 37 °C. One amidolytic unit will hydrolyze 1.0 μmole of N-p-tosyl-Gly-Pro-Arg-p-nitroanilide per min at pH 8.4 at 37 °C.

Piktogramme

Health hazard

Signalwort

Danger

H-Sätze

Gefahreneinstufungen

Resp. Sens. 1 - Skin Sens. 1

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Elise S Eerenberg et al.
Circulation, 124(14), 1573-1579 (2011-09-09)
Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of
Wei Zhou et al.
Stroke, 42(12), 3594-3599 (2011-10-15)
Dabigatran-etexilate (DE) recently has been approved for stroke prevention in atrial fibrillation. However, lack of effective antagonists represents a major concern in the event of intracerebral hemorrhage (ICH). The aims of the present study were to establish a murine model
Lambro A Johnson et al.
Analytical biochemistry, 608, 113907-113907 (2020-08-20)
Snake venom prothrombin activators such as Ecarin are readily assayed by continuous spectrophotometric monitoring of p-nitroaniline production in a one step assay containing prothrombin and a p-nitroanilide peptide substrate for thrombin. The coupled reactions result in accelerating p-nitroaniline (pNA) production
Kevin Dietrich et al.
Thrombosis research, 135(4), 630-635 (2015-02-27)
Age-related changes in the hemostatic system result in variation in response to anticoagulants and coagulation assays over childhood. This study used in vitro methods to determine i) optimum coagulation assays for dabigatran in children and ii) anticoagulant effect of dabigatran

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.